1. Home
  2. KLTO vs BCDA Comparison

KLTO vs BCDA Comparison

Compare KLTO & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KLTO
  • BCDA
  • Stock Information
  • Founded
  • KLTO 2019
  • BCDA N/A
  • Country
  • KLTO United States
  • BCDA United States
  • Employees
  • KLTO N/A
  • BCDA N/A
  • Industry
  • KLTO
  • BCDA Biotechnology: Pharmaceutical Preparations
  • Sector
  • KLTO
  • BCDA Health Care
  • Exchange
  • KLTO NYSE
  • BCDA Nasdaq
  • Market Cap
  • KLTO 8.3M
  • BCDA 7.9M
  • IPO Year
  • KLTO N/A
  • BCDA N/A
  • Fundamental
  • Price
  • KLTO $0.48
  • BCDA $2.05
  • Analyst Decision
  • KLTO
  • BCDA Strong Buy
  • Analyst Count
  • KLTO 0
  • BCDA 1
  • Target Price
  • KLTO N/A
  • BCDA $25.00
  • AVG Volume (30 Days)
  • KLTO 992.6K
  • BCDA 31.3K
  • Earning Date
  • KLTO 02-15-2025
  • BCDA 11-13-2024
  • Dividend Yield
  • KLTO N/A
  • BCDA N/A
  • EPS Growth
  • KLTO N/A
  • BCDA N/A
  • EPS
  • KLTO N/A
  • BCDA N/A
  • Revenue
  • KLTO N/A
  • BCDA $71,000.00
  • Revenue This Year
  • KLTO N/A
  • BCDA N/A
  • Revenue Next Year
  • KLTO N/A
  • BCDA N/A
  • P/E Ratio
  • KLTO N/A
  • BCDA N/A
  • Revenue Growth
  • KLTO N/A
  • BCDA N/A
  • 52 Week Low
  • KLTO $0.26
  • BCDA $1.84
  • 52 Week High
  • KLTO $13.10
  • BCDA $10.80
  • Technical
  • Relative Strength Index (RSI)
  • KLTO N/A
  • BCDA 42.16
  • Support Level
  • KLTO N/A
  • BCDA $2.00
  • Resistance Level
  • KLTO N/A
  • BCDA $2.14
  • Average True Range (ATR)
  • KLTO 0.00
  • BCDA 0.16
  • MACD
  • KLTO 0.00
  • BCDA -0.00
  • Stochastic Oscillator
  • KLTO 0.00
  • BCDA 15.91

About KLTO KLOTHO NEUROSCIENCES INC

Klotho Neurosciences Inc is in the development of patented, novel disease-modifying technologies targeting the brain and central nervous system (CNS) that are seen as key developments in treating neurodegenerative and age-related disorders.

About BCDA BioCardia Inc.

BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).

Share on Social Networks: